Joseph M Tuscano
University of California, Davis
5
4
1
N/A
0
4
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+16 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Jordan Gauthier
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Ajay Gopal
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Tanya Siddiqi
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Brenda Sandmaier
Fred Hutch/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Ryotaro Nakamura
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
chitra hosing
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Brenda Sandmaier
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Leona Holmberg
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Nitin Jain
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma
Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma
All 5 trials loaded